kat

1 year since my dad’s death. The most difficult thing I ever had to do was tell my dad he was dying. Every other obstacle is trivial in comparison. 🤍

Keytruda transformed cancer care and made Merck more money than any drug in history. It was also discovered by accident, and nearly out-licensed in 2010 for pocket change. New Approved + exclusive interviews with the inventors and the Merck CMO who ran development:

@rrhoover Congrats Ryan!!!

Announcing Weekend Fund IV, backed by operators and founders (and maybe you). When we raised Weekend Fund III, we did something different. Toward the end of our raise, we announced the fund in public and accepted applications from LPs. Our goal was to make early-stage venture more accessible and align ourselves with an army of operators and founders to help us and the startups we back. Over 1,000 people expressed interest to join and hundreds did, but there was a problem. Legally, only accredited investors could participate as an LP. Accreditation laws are well-meaning but limit access to the majority of consumers. With WF IV, @vedikaja_in and I are doing something different. Like before, we’re onboarding engineers, designers, researchers, data scientists, salespeople, and other domain experts as LPs in the fund. But this time at a larger scale with USVC. AngelList recently announced USVC, a new kind of fund that’s accessible to everyone, including the non-accredited. It holds positions in private late-stage companies like xAI, Anthropic, OpenAI, Sierra, and Vercel. I personally invested. Today, they just announced their investment in Weekend Fund IV, one of the first early-stage funds added to their portfolio. If you’re interested in being a part of Weekend Fund and getting exposure to generational startups mentioned above, visit usvc [dot] com. Of course, don’t invest what you can’t afford to lose. Investing in startups is risky and you may lose all your money. USVC shares are illiquid with no guarantee of repurchase. Consider investment objectives, risks, charges and expenses carefully before investing. Read the prospectus: usvc [dot] com/prospectus. Also, USVC is currently limited to US citizens. They’re working to open the fund to other geographies. Lastly, my DMs are open. :)

@algobaker Somehow yes

@katclone People are still talking about this?

THE DOG GOT A CHECKPOINT INHIBITOR

I will say jokes aside moments like these end up often funneling more money and attention in a field that is worth having more funding Maybe in a clinical trial cancer vaccine would’ve helped dogs

I actually cannot believe how many times I’ve heard about the dog from every imaginable social circle 😹😹

me after hearing ai cured dog cancer for the billionth time lol

@tbpn @VictorWBoyd @alexkshieh @NDobroshinsky @ishangpta @antoni_kiszka @HighPriestOfSWO @G413N @needaubrey @samuelclcc @clairebookworm @clairebookworm Claire!!!! 🥳

It's Thiel Fellowship Day: - @VictorWBoyd (Cavalla) - @alexkshieh (Antifraud) - @NDobroshinsky (EveryTicker) - @ishangpta (Juicebox) - @antoni_kiszka (Derpetual) - @HighPriestOfSWO (Opt32) - @G413N (SI) - @needaubrey (Swoop) - @samuelclcc (Praso) - @clairebookworm (Researcher)

begged my department and Bob to let me take his cancer bio class at mit as a neuro phd — best class, legend

Last August, @sytses and I traveled to Beijing for an experimental scan to look at a biomarker that’s specifically upregulated in his cancer. We were stunned. The whole experience — from international patient check-in, to preparation of the radiotracer, to injection, to imaging, to discussing the result with the physician, to leaving with a glossy printout of the whole-body scan — took two hours. This experience inspired me to return to China to understand in more depth what is happening there at the forefront of biotech and medicine. I recently spent a week visiting 5 cities across China's biotech ecosystem, meeting with companies, investigators, and research organizations. I came away impressed. What I found was a system and a community built for speed and pragmatic innovation that cares about helping patients. Interestingly, the investigator-initiated trial system in China seems to operate on a "marketplace of reputation," where trusted physicians and institutions can move promising therapies to patients quickly, with safety governed by local scientific and ethics committees and professional accountability rather than centralized bureaucracy. The implications are striking: medical tourism may soon invert, with patients flying to China for cutting-edge experimental treatments. And I hope that we in America can learn from the sensible steps the Chinese ecosystem has taken and speed up our own innovation cycle. Patients deserve it. Thanks very much to @jordanschneider and the team at ChinaTalk (especially Lily Ottinger and Nick Corvino) for publishing my thoughts on the trip. Link to post in comments.

Posting for two reasons: 1 being if any of you can help this guy out. 2 being to remind everyone that if AI can shorten (even by a little) the time it takes to get drugs like these to the people that need them, then the trillions on compute will have been well spent.

fiscally american socially european

My phone died lol close enough

BEAUTIFUL DAY FOR 20 MILE RUN AND WORK

@JohnSchloendorn Yeah single nuc seq would be fine too I think. Ideally looking for a provider that has benchmarked results to other preservation methods

@katclone Cytosolic mRNA is going to be a mess. You'll get data, but you can't trust that the single cell separation is complete imo. At this point, intact nuclei isolation is your best bet. It does show you some semblance of transcriptome in the context of ongoing processing / traffic

Which companies have experience doing single cell sequencing from OCT frozen tumor samples? Pls DM / share !!

I see why my friend asked for a snap and go lol

you’re telling me THIS LOOK costs $949?????

new forbes 30 under 30 model where you pay to stay off the list

Today we’re launching the newest version of @paradigmai When we started Paradigm, the goal was never to tack AI onto existing spreadsheets. It was to build a new type of interface that does the work for you. Now we’re pushing that vision much further. Workflows turn Paradigm into a system that runs research processes for you. Connect your CRM, existing spreadsheets, Slack, email, and internal data, and let Paradigm continuously run the research workflows your team already does. Same intuitive interface. But now a system of action. If you tried Paradigm before, try it again. Manual research is now a competitive liability.